Bonus Content - Accredited Activities

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 1 of the activity, including how MCED testing is helping to address the cancer screening gap in the US and the importance of staying up to date on developments in MCED testing. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. 

Click here to claim your CME credit: https://bit.ly/3X8apxa

Additional Advances in MCED Technologies: The Impact of MCED Testing + Module 1 Activity

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 2 of the activity, including the value of MCED testing for cancer survivors and ongoing trials investigating MCEDs that he’s looking forward to seeing results of in the near future. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. 

Click here to claim your CME credit: https://bit.ly/41rS14I

Additional Advances in MCED Technologies: Cancer Survivorship and Emerging Trials + Module 2 Activity

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 3 of the activity, including questions he commonly gets from patients about MCED testing and advice for clinicians about employing shared decision making with patients to choose the most appropriate type of cancer screening for them. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit. 

Click here to claim your CME credit: https://bit.ly/4b9JU00

Additional Advances in MCED Technologies: MCED Testing and Shared Decision Making + Module 3 Activity

As we recognize Kidney Cancer Awareness Month this March, advancements in renal cell carcinoma (RCC) treatment continue to evolve. Recently, Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, a Nurse Practitioner and expert in genitourinary oncology, chaired the i3 Health’s NCPD activity titled Toxicity Management and Symptom Control in Advanced RCC: Playbook Update. In this interview, she shares updates in RCC treatment, strategies for toxicity management, and the importance of patient education.

Click here for the full NCPD activity! https://i3health.com/course-information/toxicity-management-and-symptom-control-in-advanced-rcc-playbook-update

Additional Advances in Renal Cell Carcinoma Research and Clinical Trials With Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC

March marks Multiple Myeloma Awareness Month, a crucial time to highlight advances in the treatment of this complex blood cancer. Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center, is currently serving as chair of i3 Health CME/NCPD activity, Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma. In this interview, Dr. Hashmi shares additional insights into the evolving role of transplantation in this disease and the importance of education and advocacy during Multiple Myeloma Awareness Month.   



Click the link for the full activity! https://bit.ly/4hyVwLn

Additional Advances in Stem Cell Mobilization Research and Clinical Trials in Multiple Myeloma With Hamza Hashmi, MD


Join i3 Health for a special live webinar, Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, being held on Thursday, July 17th at 12:00 pm Eastern and on Tuesday, August 5th at 3:00 pm Eastern. In this exclusive event, Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, will share his expertise and latest insights in the treatment of NETs.

In this interview, Dr. Chauhan shares a preview of the topics he is excited to highlight during the webinar, including the recent advances which are transforming patient care, the emerging field of theranostics, the evolving role of multidisciplinary care, and practical tips for effective team collaboration.

Don’t miss this opportunity to learn from one of the leading voices in NETs care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!

Register Here! 

July 17, 2025 @ 12:00 PM ET: https://us02web.zoom.us/webinar/register/WN_2VJ0PmYISae4gAh2KxNlnQ#/registration

August 5, 2025 @ 3:00 PM ET: https://us02web.zoom.us/webinar/register/WN_teUE5QgyQJ6sYaLRrkNp9g#/registration

Exploring the Evolution of Neuroendocrine Tumor Diagnostics and Therapeutics: A Webinar Preview With Aman Chauhan, MD

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Exploring the Evolution of Neuroendocrine Tumor Diagnostics and Therapeutics: A Webinar Preview With Aman Chauhan, MD

Oncology Data Advisor®